131694 20260217205515.0 doi 10.1111/jdv.19570 sideral 137136 ART-2024-137136 eng Chernyshov, P. V. Quality of life measurement in teledermatology. Position statement of the european academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and teledermatology 2024 Many events, including the COVID‐19 pandemic, have accelerated the implementation of teledermatology pathways within dermatology departments and across healthcare organizations. Quality of Life (QoL) assessment in dermatology is also a rapidly developing field with a gradual shift from theory to practice. The purpose of this paper organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and patient‐oriented outcomes and the EADV TF on teledermatology is to present current knowledge about QoL assessment during the use of teledermatology approaches, including data on health‐related (HR) QoL instruments used in teledermatology, comparison of influence of different treatment methods on HRQoL after face‐to‐face and teledermatology consultations and to make practical recommendations concerning the assessment of QoL in teledermatology. The EADV TFs made the following position statements: HRQoL assessment may be an important part in most of teledermatology activities; HRQoL assessment may be easily and effectively performed during teledermatology consultations. It is especially important to monitor HRQoL of patients with chronic skin diseases during lockdowns or in areas where it is difficult to reach a hospital for face‐to‐face consultation; regular assessment of HRQoL of patients with skin diseases during teledermatology consultations may help to monitor therapy efficacy and visualize individual patient's needs; we recommend the use of the DLQI in teledermatology, including the use of the DLQI app which is available in seven languages; it is important to develop apps for dermatology‐specific HRQoL instruments for use in children (for example the CDLQI and InToDermQoL) and for disease‐specific instruments. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 8.0 2024 DERMATOLOGY 6 / 96 = 0.062 2024 Q1 T1 2.154 2024 Infectious Diseases 2024 Q1 Dermatology 2024 Q1 11.1 2024 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Finlay, A. Y. Tomas-Aragones, L. (orcid)0000-0003-1917-6906 Tognetti, L. Moscarella, E. Pasquali, P. Manolache, L. Pustisek, N. Svensson, A. Marron, S. E. Universidad de Zaragoza (orcid)0000-0001-5632-0351 Bewley, A. Salavastru, C. Suru, A. Koumaki, D. Linder, D. Abeni, D. Augustin, M. Blome, C. Salek, S. S. Evers, A. W. M. Poot, F. Sampogna, F. Szepietowski, J. ¿. 1007 183 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Área Dermatología 38, 2 (2024), 254-264 JEADV, J. Eur. Acad. Dermatol. Venereol. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 0926-9959 452096 http://zaguan.unizar.es/record/131694/files/texto_completo.pdf Postprint 2212509 http://zaguan.unizar.es/record/131694/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:131694 articulos driver 2026-02-17-20:26:47 ARTICLE